This article has been corrected to reflect that the Lee et al. paper was published in Nature in May.
It was a mutually beneficial partnership from the start. Genentech, the Roche subsidiary, was looking for ways to cut whole-genome sequencing costs. Thirty miles south along the San Francisco Bay a sequencing-as-a-service startup was searching for collaborators to bring its proprietary approach to market.